{"id":"https://openalex.org/W2000251422","doi":"https://doi.org/10.1021/jm950894b","title":"7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics","display_name":"7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W2000251422","doi":"https://doi.org/10.1021/jm950894b","mag":"2000251422","pmid":"https://pubmed.ncbi.nlm.nih.gov/8709130"},"language":"en","primary_location":{"id":"doi:10.1021/jm950894b","doi":"https://doi.org/10.1021/jm950894b","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm950894b","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112447056","display_name":"Jordi De Bol\u00f3s","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jordi Bol\u00f3s","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058847628","display_name":"Santiago Gubert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Santiago Gubert","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Llu\u00eds Anglada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Llu\u00eds Anglada","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103683721","display_name":"Josep M. Planas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Josep M. Planas","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010959032","display_name":"Carme Burgarolas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Carme Burgarolas","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025252246","display_name":"J. M. CASTELLO","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Josep M. Castell\u00f3","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108414158","display_name":"Aurelio Sacristan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Aurelio Sacrist\u00e1n","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]},{"author_position":"last","author":{"id":null,"display_name":"Jos\u00e9 A. Ortiz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094501","display_name":"Ferrer Grupo (Spain)","ror":"https://ror.org/00mwcg389","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210094501"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jos\u00e9 A. Ortiz","raw_affiliation_strings":["Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Grupo Ferrer, Juan de Sada, 32, 08028-Barcelona, Spain","institution_ids":["https://openalex.org/I4210094501"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210094501"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":1.2535,"has_fulltext":false,"cited_by_count":53,"citation_normalized_percentile":{"value":0.77967859,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"39","issue":"15","first_page":"2962","last_page":"2970"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.5800999999046326,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.5800999999046326,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.20010000467300415,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T13023","display_name":"Synthesis of Organic Compounds","score":0.058400001376867294,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9589999914169312},{"id":"https://openalex.org/keywords/chromenone","display_name":"chromenone","score":0.6890000104904175},{"id":"https://openalex.org/keywords/piperazine-derivatives","display_name":"piperazine derivatives","score":0.7289999723434448},{"id":"https://openalex.org/keywords/piperidine-derivatives","display_name":"piperidine derivatives","score":0.8880000114440918},{"id":"https://openalex.org/keywords/apomorphine-induced-climbing","display_name":"apomorphine-induced climbing","score":0.7409999966621399},{"id":"https://openalex.org/keywords/hyperactivity","display_name":"hyperactivity","score":0.8109999895095825},{"id":"https://openalex.org/keywords/stereotyped-behavior","display_name":"stereotypy","score":0.8159999847412109},{"id":"https://openalex.org/keywords/catalepsy","display_name":"catalepsy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.9580000042915344},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8820000290870667},{"id":"https://openalex.org/keywords/structure-activity-optimization","display_name":"structure-activity optimization","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8356074094772339},{"id":"https://openalex.org/C2781462491","wikidata":"https://www.wikidata.org/wiki/Q410234","display_name":"Piperidine","level":2,"score":0.6849686503410339},{"id":"https://openalex.org/C2780476085","wikidata":"https://www.wikidata.org/wiki/Q918193","display_name":"Catalepsy","level":4,"score":0.5998938083648682},{"id":"https://openalex.org/C2777525119","wikidata":"https://www.wikidata.org/wiki/Q269111","display_name":"Apomorphine","level":4,"score":0.5816700458526611},{"id":"https://openalex.org/C2776201271","wikidata":"https://www.wikidata.org/wiki/Q409292","display_name":"Piperazine","level":2,"score":0.5798890590667725},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5629124641418457},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5539414882659912},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.5075277090072632},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.4308868944644928},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.33874011039733887},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.1960567831993103},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13196298480033875},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.1280861794948578},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.12398430705070496},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.12179282307624817},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.08867564797401428},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.08257481455802917},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.08212023973464966},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0776662826538086},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.06705349683761597}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001058","descriptor_name":"Apomorphine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001522","descriptor_name":"Behavior, Animal","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002375","descriptor_name":"Catalepsy","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013239","descriptor_name":"Stereotyped Behavior","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm950894b","doi":"https://doi.org/10.1021/jm950894b","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm950894b","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:8709130","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8709130","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W119245859","https://openalex.org/W2009447429","https://openalex.org/W2014526252","https://openalex.org/W2016325006","https://openalex.org/W2018507547","https://openalex.org/W2028777335","https://openalex.org/W2029179744","https://openalex.org/W2040657121","https://openalex.org/W2050573750","https://openalex.org/W2056516679","https://openalex.org/W2067640929","https://openalex.org/W2067678628","https://openalex.org/W2073711860","https://openalex.org/W2076279142","https://openalex.org/W2344660540","https://openalex.org/W2475119877"],"related_works":["https://openalex.org/W2952657662","https://openalex.org/W2949177121","https://openalex.org/W1983137703","https://openalex.org/W2950635345","https://openalex.org/W2057665336","https://openalex.org/W2038522197","https://openalex.org/W2006420319","https://openalex.org/W2051656457","https://openalex.org/W2949400810","https://openalex.org/W2001883557"],"abstract_inverted_index":{"Compound":[0],"1":[1],"(1-benzyl-3-methyl-4-[4-(4-fluorophenyl)-4-oxobutyl]piperazine),":[2],"a":[3,8,40,116],"synthetic":[4],"intermediate":[5],"identified":[6],"as":[7,14,69],"potential":[9],"atypical":[10,108],"antipsychotic,":[11],"was":[12],"selected":[13],"the":[15,57,83],"starting":[16],"point":[17],"for":[18,102],"pharmacological":[19],"improvement.":[20],"From":[21],"1,":[22],"sequential":[23],"structural":[24],"variations":[25,38],"were":[26],"conducted":[27],"in":[28,56,64,94,123],"order":[29],"to":[30,82,114],"improve":[31],"its":[32],"potency":[33],"and":[34,45,62,90],"oral":[35],"bioavailability.":[36],"These":[37],"included":[39],"series":[41,50],"of":[42,59,73,78,88,92,104,119],"piperazine,":[43],"ethanediamine,":[44],"piperidine":[46,49],"derivatives.":[47],"The":[48],"afforded":[51],"some":[52],"orally":[53],"potent":[54,85],"compounds":[55],"inhibition":[58,103],"apomorphine-induced":[60],"climbing":[61,105],"hyperactivity":[63],"mice,":[65],"which":[66,111],"are":[67],"regarded":[68],"behavioral":[70],"models":[71],"predictive":[72],"antipsychotic":[74,109],"efficacy.":[75],"Further":[76],"optimization":[77],"these":[79],"structures":[80],"led":[81],"highly":[84],"7-[3-(1-piperidinyl)propoxy]chromenones.":[86],"Inhibition":[87],"stereotypies":[89],"induction":[91,118],"catalepsy":[93],"rats":[95],"at":[96],"doses":[97],"substantially":[98],"higher":[99],"than":[100],"required":[101],"suggest":[106],"an":[107],"profile,":[110],"is":[112],"assumed":[113],"predict":[115],"reduced":[117],"extrapyramidal":[120],"side":[121],"effects":[122],"humans.":[124]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}